Advances in molecular biology and the possibility of differentiating stem cells have opened up new scenarios in therapies that use progenitor or variously differentiated cells. In this paper published on Biotechnology and Bioengineering, our team illustrates the advantages of using closed systems (isolators) for the production of ATMPs.

In questo articolo appena pubblicato su NCF, il TEAM BIOAIR descrive una soluzione specifica per le terapie avanzate l’ISOCELLBOX che consente il trasferimento bioconfinato di cellule in coltura in condizioni asettiche e in compliance con le GMP.